Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with Pranlukast, a novel leukotriene receptor antagonist

Jay Grossman, Isidore Faiferman, Jeffrey W. Dubb, Debra J. Tompson, William Busse, Edwin Bronsky, Anthony Montanaro, Loren Southern, David Tinkelman

Research output: Contribution to journalArticlepeer-review

70 Scopus citations

Abstract

Pranlukast (SB 205312; ONO-1078), a potent, orally active selective cysteinyl-leukotriene receptor antagonist (LTRA), was developed in Japan for the treatment of asthma. This article reports results of the initial U.S. clinical evaluation of pranlukast. The primary objective of this multicenter study was to evaluate the safety and tolerability of pranlukast administered at doses of 337.5 mg b.i.d. and 450 mg b.i.d. in 65 patients with mild to moderate asthma. Pranlukast, a novel LTRA, is safe and well tolerated at doses of 337.5 mg b.i.d. and 450 mg b.i.d. Pranlukast has demonstrated clinical activity in patients with asthma.

Original languageEnglish (US)
Pages (from-to)321-328
Number of pages8
JournalJournal of Asthma
Volume34
Issue number4
DOIs
StatePublished - Jan 1 1997

Keywords

  • Asthma
  • Clinical trial
  • Leukotriene receptor antagonist
  • ONO-1078
  • Pranlukast
  • SB 205312

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with Pranlukast, a novel leukotriene receptor antagonist'. Together they form a unique fingerprint.

Cite this